A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

Active:	Yes
Cancer Type:	Liver Cancer / Hepatoblastoma	NCT ID:	NCT06084884
Trial Phases:	Phase I Phase II	Protocol IDs:	D7670C00001 (primary) NCI-2023-10232
Eligibility:	18 - 130 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT06084884

Summary

A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent
hepatocellular carcinoma.

Objectives

This first-time in human, single-arm, open-label multicentre Phase I/II study will
evaluate the safety, tolerability, antitumour activity, cellular kinetics,
pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+
advanced/recurrent HCC, where at least one line of prior therapy has failed/or was
intolerable, or participant/investigator decision.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.